

Giovanni Paganelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3655686/publications.pdf>

Version: 2024-02-01

257
papers

16,857
citations

17776

65
h-index

18944

123
g-index

265
all docs

265
docs citations

265
times ranked

11206
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome. <i>Molecular Oncology</i> , 2022, 16, 538-548.	2.1	4
2	Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device. <i>Scientific Reports</i> , 2022, 12, 14.	1.6	1
3	Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 191-214.	2.5	3
4	Theragnostic in neuroendocrine tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.4	2
5	On the Way for Patients with Prostate Cancer to the Best Use of PSMA. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2478.	1.8	0
6	Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab. <i>Scientific Reports</i> , 2022, 12, 3385.	1.6	4
7	Radiomics Analysis on [68Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial. <i>Cancers</i> , 2022, 14, 1888.	1.7	12
8	177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 152-160.	3.3	20
9	Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	1.4	19
10	Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3260-3267.	3.3	29
11	Exploratory Analysis of 18F-3 TM -deoxy-3 TM -fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 601053.	1.3	11
12	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	2.9	13
13	Targeted radioactive therapy for prostate cancer. <i>Lancet, The</i> , 2021, 398, 487-488.	6.3	0
14	177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Biomedicines</i> , 2021, 9, 1042.	1.4	10
15	Diagnostic and Prognostic Potential of 18F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After Chemoradiation Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 721821.	1.3	14
16	Avidin-biotin approach for cancer therapy and new biotin derivatives. , 2021, , .		0
17	PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 895-906.	3.3	73
18	SUV95th as a Reliable Alternative to SUVmax for Determining Renal Uptake in [68Ga] PSMA PET/CT. <i>Molecular Imaging and Biology</i> , 2020, 22, 1070-1077.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Dosimetric Issues Associated with Percutaneous Ablation of Small Liver Lesions with 90Y. Applied Sciences (Switzerland), 2020, 10, 6605.	1.3	3
20	68Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. Biomedicines, 2020, 8, 536.	1.4	11
21	Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 9054.	1.8	32
22	Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen). Frontiers in Oncology, 2020, 10, 531660.	1.3	15
23	Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3008-3017.	3.3	37
24	A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2223-2226.	3.3	2
25	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2372-2382.	3.3	79
26	A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. Journal of Visualized Experiments, 2020, .	0.2	8
27	PET/CT in Multiple Myeloma: Beyond FDG. Frontiers in Oncology, 2020, 10, 622501.	1.3	24
28	Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic. Insights Into Imaging, 2020, 11, 129.	1.6	6
29	Texture analysis in 177Lu SPECT phantom images: Statistical assessment of uniformity requirements using texture features. PLoS ONE, 2019, 14, e0218814.	1.1	3
30	CAR-T cell therapy: a potential new strategy against prostate cancer. , 2019, 7, 258.		61
31	Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report. Journal of Contemporary Brachytherapy, 2019, 11, 449-457.	0.4	27
32	Early use of abiraterone and radium-223 in metastatic prostate cancer. Lancet Oncology, The, 2019, 20, e228.	5.1	7
33	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. JCO Precision Oncology, 2019, 3, 1-13.	1.5	8
34	Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol. Molecules, 2019, 24, 621.	1.7	34
35	A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions. Scientific Reports, 2019, 9, 5623.	1.6	2
36	Intego™ infusion system: cost effectiveness analysis focusing on dosimetry, sterility and management. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 183-190.	0.4	0

#	ARTICLE	IF	CITATIONS
37	PRRT genomic signature in blood for prediction of ¹⁷⁷ Lu-octreotate efficacy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1155-1169.	3.3	101
38	Investigation of receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 923-930.	3.3	56
39	PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. <i>Scientific Reports</i> , 2018, 8, 4254.	1.6	128
40	Prognostic value of ¹⁸ F- α -choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 348-354.	3.3	22
41	Role of Functional Imaging in the Diagnosis of Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 109-121.	0.0	0
42	⁶⁸ Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2035-2044.	3.3	72
43	[¹⁷⁷ Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?. <i>Lancet Oncology</i> , The, 2018, 19, 725-726.	5.1	9
44	⁶⁸ Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer. <i>Radiologia Medica</i> , 2018, 123, 952-965.	4.7	16
45	Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1777-1778.	3.3	1
46	Reduction of ⁶⁸ Ga-PSMA renal uptake with mannitol infusion: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2189-2194.	3.3	30
47	Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with ¹⁷⁷ Lu-D OTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 490-499.	3.3	95
48	Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO). <i>Ecancermedalscience</i> , 2017, 11, 744.	0.6	1
49	Quantitative accuracy of ¹⁷⁷ Lu SPECT imaging for molecular radiotherapy. <i>PLoS ONE</i> , 2017, 12, e0182888.	1.1	21
50	Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 551-557.	1.0	37
51	Therapeutic schemes in ¹⁷⁷ Lu and ⁹⁰ Y-PRRT: radiobiological considerations. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 216-231.	0.4	15
52	Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors. , 2017, , 799-838.		0
53	Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. , 2017, , 1243-1267.		1
54	Nuclear Medicine in the Clinical Management (ROLL, SNB, and PET). , 2017, , 247-264.		0

#	ARTICLE	IF	CITATIONS
55	Peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and ¹⁸ F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1040-1046.	3.3	77
56	Long-term results of PRRT in advanced bronchopulmonary carcinoid. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 441-452.	3.3	103
57	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine Connections, 2016, 5, 174-187.	0.8	83
58	Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. , 2016, , 1-26.		0
59	Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors. , 2016, , 1-40.		0
60	Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers. Organic and Biomolecular Chemistry, 2015, 13, 3988-4001.	1.5	7
61	Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 5-19.	3.3	357
62	¹⁸ F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1276-1283.	3.3	83
63	Development of sentinel node localization and ROLL in breast cancer in Europe. Clinical and Translational Imaging, 2015, 3, 171-178.	1.1	2
64	Feasibility and utility of re-treatment with ¹⁷⁷ Lu-DOTATATE in GEP-NENs relapsed after treatment with ⁹⁰ Y-DOTATOC. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1955-1963.	3.3	62
65	Positron emission tomography in the diagnostic work-up of screening-detected lung nodules. European Respiratory Journal, 2015, 45, 501-510.	3.1	49
66	ecancermedalscience. Ecancermedalscience, 2014, 8, 414.	0.6	12
67	Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2090-2092.	3.3	14
68	⁶⁸ Ga ⁶⁸ DOTA-Tyr ³ octreotide (⁶⁸ DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours. Clinical Endocrinology, 2014, 81, 152-153.	1.2	11
69	Efficacy of ⁹⁰ Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma. Hematological Oncology, 2014, 32, 10-15.	0.8	24
70	Ipilimumab-Induced Immunomediated Adverse Events. Clinical Nuclear Medicine, 2014, 39, 472-474.	0.7	14
71	Hibernoma Mimicking Metastasis on Positron Emission Tomography-Computed Tomography Imaging: A Misleading Finding in Oncologic Patient Follow-up. Breast Journal, 2014, 20, 87-89.	0.4	5
72	¹⁷⁷ Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1845-1851.	3.3	103

#	ARTICLE	IF	CITATIONS
73	Yttrium-Based Therapy for Neuroendocrine Tumors. PET Clinics, 2014, 9, 71-82.	1.5	8
74	Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors. Thoracic Surgery Clinics, 2014, 24, 333-349.	0.4	52
75	Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget, 2014, 5, 12448-12458.	0.8	92
76	ecancermedalscience. Ecancermedalscience, 2013, 7, 329.	0.6	5
77	Treatment with the Radiolabelled Somatostatin Analog ^{177}Lu -DOTATATE for Advanced Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2013, 97, 347-354.	1.2	104
78	PET/CT and breast cancer subtypes. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1301-1303.	3.3	5
79	Role of 18FDG PET/CT in patients treated with ^{177}Lu -DOTATATE for advanced differentiated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 881-888.	3.3	123
80	Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions. Breast Cancer Research and Treatment, 2013, 139, 287-290.	1.1	3
81	Neuroendocrine Tumors. , 2013, , 491-520.		2
82	Local Accelerated Radionuclide Breast Irradiation: Avidin-Biotin Targeting System. , 2013, , 165-175.		0
83	Investigation of ^{90}Y -avidin for prostate cancer brachytherapy: a dosimetric model for a phase II clinical study. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1047-1056.	3.3	9
84	Radioimmunotherapy in Brain Tumors. , 2013, , 113-131.		0
85	Is ^{18}F fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?. Breast, 2013, 22, 39-43.	0.9	29
86	Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with ^{18}F fluoroestradiol (^{18}F -FES) PET/CT.. Journal of Clinical Oncology, 2013, 31, TPS649-TPS649.	0.8	0
87	Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies. Journal of Nuclear Medicine, 2012, 53, 922-927.	2.8	65
88	Intracavitary Use of Radionuclides and Treatment of Meningiomas. Medical Radiology, 2012, , 207-214.	0.0	0
89	Le indicazioni alla terapia radiorecettoriale nei tumori neuroendocrini. L Endocrinologo, 2012, 13, 107-112.	0.0	0
90	3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART [®]) combined with external beam radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1702-1711.	3.3	14

#	ARTICLE	IF	CITATIONS
91	Preoperative FDG PET/CT in breast cancer patients: where are we going?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1667-1669.	3.3	2
92	Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support. Medical Radiology, 2012, , 543-550.	0.0	0
93	Yttrium-labelled peptides for therapy of NET. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 93-102.	3.3	49
94	Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy. Annals of Hematology, 2012, 91, 299-300.	0.8	4
95	The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients. Blood, 2012, 120, 4876-4876.	0.6	2
96	Calculation of electron and isotopes dose point kernels with <scp>fluka</scp> Monte Carlo code for dosimetry in nuclear medicine therapy. Medical Physics, 2011, 38, 3944-3954.	1.6	62
97	Preclinical Pharmacology and Safety of a Novel Avidin Derivative for Tissue-Targeted Delivery of Radiolabelled Biotin. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 145-155.	1.2	10
98	SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes. Surgery, 2011, 150, 1136-1142.	1.0	3
99	Dosimetry Using SPECT-CT. , 2011, , 213-225.		0
100	Peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE: the IEO phase I-II study. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2125-2135.	3.3	349
101	Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2096-2097.	3.3	1
102	PET imaging of HER-2-positive tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1961-1963.	3.3	0
103	The Hypofunctional Effect of P335L Single Nucleotide Polymorphism on SSTR5 Function. World Journal of Surgery, 2011, 35, 1715-1724.	0.8	16
104	Peptide Receptor Radionuclide Therapy in a Case of Multiple Spinal Canal and Cranial Paragangliomas. Journal of Clinical Oncology, 2011, 29, e171-e174.	0.8	19
105	Efficacy of ⁹⁰ yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,. Blood, 2011, 118, 3713-3713.	0.6	0
106	Sentinel Lymph Node Biopsy in Breast Cancer. Annals of Surgery, 2010, 251, 595-600.	2.1	466
107	Sentinel lymph node biopsy in pregnant patients with breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 78-83.	3.3	123
108	Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with ⁹⁰ Y-labeled biotin. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 203-211.	3.3	34

#	ARTICLE	IF	CITATIONS
109	Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 736-741.	3.3	28
110	Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1834-1841.	3.3	15
111	Is a SUV cut-off necessary in the evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2202-2202.	3.3	1
112	Computed Tomography-Guided Preoperative Radiotracer Localization of Nonpalpable Lung Nodules. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1759-1764.	0.7	70
113	10. Perspectives in the Development of Novel Treatment Approaches. <i>Tumori</i> , 2010, 96, 858-873.	0.6	0
114	Therapeutic Use of Avidin Is Not Hampered by Antiavidin Antibodies in Humans. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 563-570.	0.7	39
115	AvidinOXâ„¢ for Highly Efficient Tissue-Pretargeted Radionuclide Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 143-148.	0.7	20
116	Nonpalpable Breast Carcinomas: Long-Term Evaluation of 1,258 Cases. <i>Oncologist</i> , 2010, 15, 1248-1252.	1.9	22
117	⁶⁸ Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 669-673.	2.8	227
118	Positron emission tomography for the detection of colorectal adenomas. <i>Digestive and Liver Disease</i> , 2010, 42, 185-190.	0.4	16
119	Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin). <i>Nuclear Medicine and Biology</i> , 2010, 37, 85-93.	0.3	9
120	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. <i>Cancer Treatment Reviews</i> , 2010, 36, S87-S94.	3.4	36
121	Biotin Derivatives Carrying Two Chelating DOTA Units. Synthesis, in Vitro Evaluation of Biotinidases Resistance, Avidin Binding, and Radiolabeling Tests. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 432-440.	2.9	9
122	Something More than Estimating Renal Dosimetry. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 767-768.	0.7	3
123	Pretargeted Radioimmunotherapy in Cancer: An Overview. , 2010, , 80-98.		1
124	The Role of Dosimetry in the High Activity 90Y-Ibritumomab Tiuxetan Regimens: Two Cases of Abnormal Biodistribution. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 271-275.	0.7	17
125	Hematologic Toxicity and Double Autografting of Stem Cells After Myeloablative Activities of Yttrium-90â„¢Ibritumomab Tiuxetan. <i>Journal of Clinical Oncology</i> , 2009, 27, 1145-1146.	0.8	1
126	OXavidin for Tissue Targeting Biotinylated Therapeutics. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-9.	3.0	13

#	ARTICLE	IF	CITATIONS
127	Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues. <i>Clinical and Translational Oncology</i> , 2009, 11, 48-53.	1.2	20
128	Peptide receptor radionuclide therapy with ⁹⁰ Y-DOTATOC in recurrent meningioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1407-1416.	3.3	121
129	Quantitative Analysis of ⁹⁰ Y Bremsstrahlung SPECT-CT Images for Application to 3D Patient-Specific Dosimetry. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 145-154.	0.7	51
130	Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases. <i>European Journal of Cancer</i> , 2009, 45, 1381-1388.	1.3	92
131	Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-DOTATATE and ⁹⁰ Y-DOTATOC. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 659-665.	0.7	33
132	Expression of the oncofetal ED-B α containing fibronectin isoform in hematologic tumors enables ED-B α -targeted ¹³¹ I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. <i>Blood</i> , 2009, 113, 2265-2274.	0.6	153
133	Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. <i>Pituitary</i> , 2008, 11, 93-102.	1.6	50
134	Contralateral or bilateral lymph drainage revealed by breast lymphoscintigraphy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 225-229.	3.3	8
135	Role of [¹⁸ F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1316-1322.	3.3	41
136	Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰ Y-DOTATOC and ¹⁷⁷ Lu-DOTATATE: the role of associated risk factors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1847-1856.	3.3	353
137	Radioembolisation with ⁹⁰ Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2088-2096.	3.3	65
138	Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules. <i>Lung Cancer</i> , 2008, 61, 340-349.	0.9	166
139	[¹⁸ F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning. <i>Lung Cancer</i> , 2008, 61, 362-368.	0.9	14
140	Imaging of Lung Hamartomas by Multidetector Computed Tomography and Positron Emission Tomography. <i>Annals of Thoracic Surgery</i> , 2008, 86, 1769-1772.	0.7	45
141	The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. <i>Annals of Oncology</i> , 2008, 19, 1553-1560.	0.6	101
142	Circulating Levels of VCAM and MMP-2 May Help Identify Patients with More Aggressive Prostate Cancer. <i>Current Cancer Drug Targets</i> , 2008, 8, 199-206.	0.8	23
143	Comparative Evaluation of an Extensive Histopathologic Examination and a Real-Time Reverse-Transcription-Polymerase Chain Reaction Assay for Mammaglobin and Cytokeratin 19 on Axillary Sentinel Lymph Nodes of Breast Carcinoma Patients. <i>Annals of Surgery</i> , 2008, 247, 136-142.	2.1	98
144	Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma. <i>Melanoma Research</i> , 2008, 18, 373-377.	0.6	9

#	ARTICLE	IF	CITATIONS
145	Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma In Situ of the Breast. <i>Annals of Surgery</i> , 2008, 247, 315-319.	2.1	124
146	Multidisciplinary Approach including Receptor Radionuclide Therapy with 90Y-DOTATOC ([90Y-DOTA0,Tyr3]-OCTREOTIDE) and 177Lu-DOTATATE ([177Lu-DOTA0,Tyr3]-OCTREOTATE) in Ectopic Cushing Syndrome from Ametastatic Gastrinoma: A Promising Proposal. <i>Endocrine Practice</i> , 2008, 14, 213-218.	1.1	7
147	Radioguided Occult Lesion Localization in the Breast. , 2008, , 226-232.		2
148	Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90Y - Ibritumomab Tiuxetan.. <i>Blood</i> , 2008, 112, 2187-2187.	0.6	2
149	Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 3063-3063.	0.6	1
150	A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. <i>Annals of Oncology</i> , 2007, 18, 473-478.	0.6	154
151	Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 5646s-5651s.	3.2	22
152	High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1871-1879.	2.8	49
153	Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. <i>Blood</i> , 2007, 110, 54-58.	0.6	171
154	Oligometastatic Nonâ€“Small Cell Lung Cancer: A Multidisciplinary Approach in the Positron Emission Tomographic Scan Era. <i>Annals of Thoracic Surgery</i> , 2007, 83, 231-234.	0.7	30
155	Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening. <i>Annals of Thoracic Surgery</i> , 2007, 84, 959-966.	0.7	72
156	Sentinel lymph node biopsy is feasible even after total mastectomy. <i>Journal of Surgical Oncology</i> , 2007, 95, 175-179.	0.8	35
157	High activity ⁹⁰ Yâ€“ibritumomab tiuxetan (Zevalin ^{Â®}) with peripheral blood progenitor cells support in patients with refractory/resistant Bâ€“cell nonâ€“Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2007, 139, 590-599.	1.2	45
158	IART ^{Â®} : Intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation. <i>Breast</i> , 2007, 16, 17-26.	0.9	28
159	The evolution of the conservative approach to breast cancer. <i>Breast</i> , 2007, 16, 120-129.	0.9	38
160	Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response. <i>Breast</i> , 2007, 16, 262-270.	0.9	11
161	The sentinel node biopsy under local anesthesia in breast cancer: Advantages and problems, how the technique influenced the activity of a breast surgery department; update from the European Institute of Oncology with more than 1000 cases. <i>Breast</i> , 2007, 16, 527-532.	0.9	14
162	Pretargeted antibodyâ€“guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma. <i>European Journal of Haematology</i> , 2007, 79, 258-262.	1.1	10

#	ARTICLE	IF	CITATIONS
163	Occult Breast Lesion Localization plus Sentinel Node Biopsy (SNOLL): Experience with 959 Patients at the European Institute of Oncology. <i>Annals of Surgical Oncology</i> , 2007, 14, 2928-2931.	0.7	81
164	Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRITÁ®). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 68-77.	3.3	42
165	Radioguided localisation (ROLL) of non-palpable breast lesions and simultaneous sentinel lymph node biopsy (SNOLL): the experience of the European Institute of Oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 957-958.	3.3	19
166	Sentinel node in breast cancer procedural guidelines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 2154-2159.	3.3	114
167	Lymphoscintigraphy and sentinel node biopsy in breast cancer: where are we after 10 years?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 2152-2153.	3.3	7
168	High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.. <i>Blood</i> , 2007, 110, 1890-1890.	0.6	3
169	Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).. <i>Blood</i> , 2007, 110, 4499-4499.	0.6	4
170	Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. <i>Lancet Oncology</i> , The, 2006, 7, 983-990.	5.1	416
171	Clinical Application of Spectral Electromagnetic Interaction in Breast Cancer: Diagnostic Results of a Pilot Study. <i>Tumori</i> , 2006, 92, 207-212.	0.6	9
172	Sentinel node detection and radioguided occult lesion localization in breast cancer. <i>Physica Medica</i> , 2006, 21, 20-23.	0.4	2
173	Radiation protection in radionuclide therapies with 90Y-conjugates: risks and safety. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1321-1327.	3.3	54
174	Radioimmunotherapy of brain tumor. <i>Neurological Research</i> , 2006, 28, 518-522.	0.6	43
175	Low and High Tenascin-Expressing Tumors Are Efficiently Targeted by ST2146 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2006, 12, 2191-2196.	3.2	26
176	Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 823-834.	0.8	327
177	High Dose 90Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.. <i>Blood</i> , 2006, 108, 2720-2720.	0.6	11
178	Efficacy of 90Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin's Lymphoma.. <i>Blood</i> , 2006, 108, 2771-2771.	0.6	2
179	Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC. <i>Journal of Nuclear Medicine</i> , 2006, 47, 105-12.	2.8	20
180	Dosimetry in Peptide radionuclide receptor therapy: a review. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1467-75.	2.8	131

#	ARTICLE	IF	CITATIONS
181	Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy. <i>Annals of Surgery</i> , 2005, 241, 319-325.	2.1	223
182	Second Biopsy of Axillary Sentinel Lymph Node for Reappearing Breast Cancer After Previous Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2005, 12, 895-899.	0.7	69
183	Sentinel lymph node biopsy for localised ductal carcinoma in situ?. <i>Breast</i> , 2005, 14, 520-522.	0.9	78
184	Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. <i>Cancer</i> , 2005, 103, 492-500.	2.0	191
185	Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005, 72, 125-131.	1.4	39
186	The sentinel lymph node biopsy under local anesthesia in breast carcinoma: experience of the European Institute of Oncology and impact on quality of life. <i>Breast Cancer Research and Treatment</i> , 2005, 89, 69-74.	1.1	18
187	The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology. <i>Breast Cancer Research and Treatment</i> , 2005, 89, 159-163.	1.1	87
188	Conservative Treatment of Breast Cancer: Its Evolution. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 195-198.	1.1	27
189	Development of axillary surgery in breast cancer. <i>Annals of Oncology</i> , 2005, 16, 259-262.	0.6	47
190	Improved Tumor Targeting by Combined Use of Two Antitenascin Antibodies. <i>Clinical Cancer Research</i> , 2005, 11, 7137s-7145s.	3.2	33
191	Preparation and characterization of active site protected poly(ethylene glycol)â€œavidin bioconjugates. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2005, 1726, 57-66.	1.1	17
192	Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. <i>European Journal of Cancer</i> , 2005, 41, 231-237.	1.3	163
193	High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.. <i>Blood</i> , 2005, 106, 488-488.	0.6	12
194	Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. <i>Journal of Nuclear Medicine</i> , 2005, 46 Suppl 1, 62S-6S.	2.8	103
195	Safety of sentinel node biopsy in pregnant patients with breast cancer. <i>Annals of Oncology</i> , 2004, 15, 1348-1351.	0.6	193
196	Lymphoscintigraphy: A method to detect unexpected sites of drainage of breast cancer. <i>Surgery</i> , 2004, 135, 566-567.	1.0	0
197	Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with 90Y-biotin?. <i>Gynecologic Oncology</i> , 2004, 93, 691-698.	0.6	37
198	Sentinel node detection in pre-operative axillary staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, S46-S55.	3.3	29

#	ARTICLE	IF	CITATIONS
199	Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1038-46.	3.3	187
200	Antibody-based cancer therapies: back to "œpolyclonals"?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1453-1455.	3.3	4
201	Lymphoscintigraphic and intraoperative detection of the sentinel lymph node in breast cancer patients: The nuclear medicine perspective. <i>Journal of Surgical Oncology</i> , 2004, 85, 112-122.	0.8	55
202	Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 65-71.	0.7	94
203	The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. <i>Nuclear Medicine Communications</i> , 2004, 25, 651-656.	0.5	123
204	Targeted bone marrow radioablation with 153Samarium-lexidronam promotes allogeneic hematopoietic chimerism and donor-specific immunologic hyporesponsiveness. <i>Transplantation</i> , 2004, 77, 647-655.	0.5	12
205	Sentinel node biopsy in male breast cancer. <i>Nuclear Medicine Communications</i> , 2004, 25, 139-143.	0.5	62
206	Clinical Utility of ^{99m} Tc-Sestamibi Scintimammography in the Management of Equivocal Breast Lesions. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 621-626.	0.7	1
207	Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 207-216.	3.3	268
208	Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 773-776.	3.3	33
209	Localization of Avidin in Superficial Bladder Cancer: A Potentially New Approach for Radionuclide Therapy. <i>European Urology</i> , 2003, 44, 556-559.	0.9	19
210	Sentinel nodes scintigraphy of the internal mammary chain in breast cancer. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2003, 497, 110-113.	0.7	0
211	A New Biotin Derivative "DOTA Conjugate as a Candidate for Pretargeted Diagnosis and Therapy of Tumors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3170-3173.	2.9	43
212	Sentinel Lymph Node Metastasis in Microinvasive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2003, 10, 1160-1165.	0.7	78
213	A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 546-553.	13.9	1,960
214	Characterization of poultry egg-white avidins and their potential as a tool in pretargeting cancer treatment. <i>Biochemical Journal</i> , 2003, 372, 219-225.	1.7	52
215	Axillary Sentinel Lymph Node Biopsy in Patients With Pure Ductal Carcinoma In Situ of the Breast. <i>Archives of Surgery</i> , 2003, 138, 309.	2.3	142
216	Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study. <i>British Journal of Cancer</i> , 2002, 86, 207-212.	2.9	149

#	ARTICLE	IF	CITATIONS
217	Radioguided occult lesion localization (ROLL) in breast cancer: maximizing efficacy, minimizing mutilation. <i>Annals of Oncology</i> , 2002, 13, 1839-1840.	0.6	62
218	Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the european institute of oncology group. <i>Seminars in Nuclear Medicine</i> , 2002, 32, 141-147.	2.5	111
219	111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial. <i>Seminars in Nuclear Medicine</i> , 2002, 32, 148-155.	2.5	225
220	Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting. <i>Journal of Controlled Release</i> , 2002, 83, 97-108.	4.8	44
221	Optimization of antibody labeling with rhenium-188 using a pre-labeled MAG3 chelate. <i>International Journal of Pharmaceutics</i> , 2002, 248, 173-182.	2.6	6
222	Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibil. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1099-1100.	3.3	5
223	Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. <i>Journal of Nuclear Medicine</i> , 2002, 43, 811-27.	2.8	80
224	Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 426-434.	2.2	186
225	Use of technetium-99m-labeled colloid albumin for preoperative and intraoperative localization of nonpalpable breast lesions. No competing interests declared. <i>Journal of the American College of Surgeons</i> , 2000, 190, 692-698.	0.2	96
226	Detection of Sentinel Nodes by Lymphoscintigraphy and Gamma Probe Guided Surgery in Vulvar Neoplasia. <i>Tumori</i> , 2000, 86, 359-363.	0.6	43
227	Is there a role for sentinel node biopsy in early NO tongue tumors?. <i>Surgery</i> , 2000, 128, 16-21.	1.0	91
228	Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 110-120.	3.3	80
229	Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 348-357.	3.3	172
230	Clinical validation of the avidin/indium-111 biotin approach for imaging infection/inflammation in orthopaedic patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 606-614.	3.3	31
231	Biokinetics and dosimetry in patients administered with 111 In-DOTA-Tyr 3 -octreotide: implications for internal radiotherapy with 90 Y-DOTATOC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 877-886.	3.3	122
232	Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. , 1999, 85, 2433-2438.		244
233	Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. , 1999, 85, 2433.		15
234	Biochemical characterization and crystal structure of a recombinant hen avidin and its acidic mutant expressed in <i>Escherichia coli</i> . <i>FEBS Journal</i> , 1998, 256, 453-460.	0.2	36

#	ARTICLE	IF	CITATIONS
235	Three-step tumor targeting via biotin-avidin interaction as a versatile system to elicit T cell-mediated, non-MHC-restricted cytotoxic activity against neoplastic cells. , 1998, 76, 443-447.		1
236	Intraoperative localization of the sentinel node in breast cancer: Technical aspects of lymphoscintigraphic methods. , 1998, 15, 268-271.		32
237	Sentinel node biopsy: role of nuclear medicine in conservative surgery of breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 99-100.	3.3	14
238	Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1336-1339.	3.3	30
239	Sentinel node localization in cutaneous melanoma: lymphoscintigraphy with colloids and antibody fragments versus blue dye mapping. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1489-1494.	3.3	39
240	Sentinel-Node Biopsy to Avoid Axillary Dissection in Breast Cancer with Clinically Negative Lymph-Nodes. Breast Journal, 1998, 4, 63-63.	0.4	2
241	Intraoperative localization of the sentinel node in breast cancer: Technical aspects of lymphoscintigraphic methods. , 1998, 15, 268.		3
242	The Role of Nuclear Medicine in the Treatment of Liver Metastases. , 1998, , 177-187.		0
243	The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 350-351.	2.2	53
244	Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet, The, 1997, 349, 1864-1867.	6.3	1,872
245	Optimization of Axillary Lymphoscintigraphy to Detect the Sentinel Node in Breast Cancer. Tumori, 1997, 83, 539-541.	0.6	25
246	In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1455-1459.	2.2	20
247	Evaluation of four radiopharmaceuticals for imaging inflammation in a rabbit model of arthritis. Annals of Nuclear Medicine, 1996, 10, 287-291.	1.2	5
248	Avidin and ¹¹¹ In-labelled biotin scan: A new radioisotopic method for localising vascular graft infection. European Journal of Vascular and Endovascular Surgery, 1995, 10, 405-414.	0.8	16
249	Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [^{99m} Tc]PnAO-biotin. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 314.	2.2	0
250	Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [^{99m} Tc]PnAO-biotin. European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 314-321.	2.2	50
251	Avidin-biotin system in Radioimmunoguided surgery for colorectal cancer. Diseases of the Colon and Rectum, 1994, 37, 335-343.	0.7	14
252	Antibody-guided scintigraphy: targeting of the "magic bullet". European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 1138-40.	2.2	16

#	ARTICLE	IF	CITATIONS
253	Overview: Biotinylated Monoclonal Antibodies: Their Potential for Diagnosis and Therapy of Cancer. <i>Current Opinion in Therapeutic Patents</i> , 1993, 3, 1465-1474.	0.2	2
254	Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisocyanide single photon emission tomography and fluorine-18 fluoro-2-deoxy-d-glucose positron emission tomography in patients with coronary artery disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1992, 19, 874-881.	2.2	159
255	Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1992, 19, 322-9.	2.2	80
256	Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. <i>International Journal of Cancer</i> , 1990, 45, 1184-1189.	2.3	107
257	In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: A strategy to increase tumor radiolocalization. <i>International Journal of Cancer</i> , 1988, 41, 121-125.	2.3	65